AgelessRx Review: Wide Menu, Unpublished Prices

The one-sentence version

AgelessRx is the most research-literate operator in direct-to-consumer longevity — it funded, ran, and published a registered placebo-controlled rapamycin trial that missed its own primary endpoint¹, which is a level of self-disclosure almost nobody in this field attempts — and it charges no membership fee, which structurally beats every lab-gated program on our board. The problem is the price tag. Almost every treatment is advertised as "Starting at $X," and on the two products where AgelessRx does explain that number, the explanation is that it is a quarterly-plan rate, an introductory rate, or both. On rapamycin, its flagship, the real month-to-month price is not published anywhere on the public site. For a provider whose central pitch is "no membership required," that is an odd place to be opaque — and on our rubric it is the axis that costs it the grade. For where prescription longevity telehealth sits in the wider market, see longevity clinics vs lab memberships vs Rx telehealth.

What AgelessRx is, and who it's for

AgelessRx is an Ann Arbor–based telehealth pharmacy-and-prescriber network built specifically around off-label longevity prescribing. You complete an online intake, a licensed clinician reviews it and decides whether to prescribe, and the prescription is filled by what the site calls a "partnering pharmacy" and shipped to you. There is no membership, no annual fee, and no mandatory diagnostic onboarding — you can buy one treatment and nothing else.

The catalog is the widest on our board: roughly four dozen line items spanning the longevity core (rapamycin, metformin, acarbose, low-dose naltrexone, NAD+ in four delivery formats, sermorelin, glutathione), a GLP-1 track, hormone and sexual-health products, dermatology, and a testing shelf that runs from a free online phenotypic calculator up to a $949 Galleri multi-cancer screen. Verified on AgelessRx's own treatment pages in July 2026.

The buyer this suits is specific: someone who already knows which molecule they want, wants a US-licensed prescriber and a pharmacy rather than a grey-market peptide vendor, and does not want to pay $129–$155 a month for a membership wrapper before the first pill ships. That is a real and underserved buyer, and AgelessRx serves them better than any lab-gated program does.

What it actually costs — and what the headline number leaves out

Here is the part that decides the grade, so we will be precise about what is published and what is not.

Metformin is the one product where AgelessRx spells out the terms in full. Its page reads: "Quarterly — $25 / month — billed $75 quarterly | shipped quarterly — 3-month supply per shipment." That is honest and complete: $25/month is real, but you pay $75 up front, three months at a time. No month-to-month option is offered.

NAD+ injections publish the trap explicitly, in small type. The headline is "Starting at $79 / mo," and directly beneath it: "Starting price applies to 3-mo plan. Monthly and 3-mo plans." Further down the same page, the disclaimer adds: "Introductory price applies to quarterly plan." So $79 is simultaneously (a) the quarterly-plan rate, not the monthly one, and (b) an introductory rate. The monthly-plan price is not published. Neither is the post-introductory price. A buyer reading "$79/mo" has no way to compute their year-two annual cost from anything on the site.

Rapamycin — the flagship — publishes no terms at all. The page says "Starting at $65" and "As low as $65 / month," notes "Monthly & quarterly shipping options," and stops. Given the pattern on the two products that do disclose, the reasonable inference is that $65 is the quarterly rate and the monthly rate is higher — but AgelessRx does not say so, and we will not assume it. What we can say plainly: the true month-to-month price of AgelessRx rapamycin is not published on any public page. You learn it inside the intake, after you have handed over a medical history.

The rest of the catalog carries the same "Starting at" construction with no terms attached: low-dose naltrexone $25, acarbose $55, sermorelin injection $99, glutathione injection $99, NAD+ nasal spray $125/mo, NAD+ patches $160/kit, microdosing semaglutide $99/mo, microdosing tirzepatide $159/month. On the testing shelf: a lab-based phenotypic blood test $75, a Core Longevity Panel $95, an at-home methylation saliva test $170.

This is the commitment trap in its cleanest form. The number on the page is a floor achievable only by prepaying a quarter, and on at least one product only during an introductory window. It is not a lie — AgelessRx discloses it on two products, which is two more than most of this industry manages — but a price you cannot compute an annual cost from is not a transparent price, and this site grades transparency at 20% for exactly this reason. See our grading methodology and, for how the whole market prices itself, how much a longevity clinic costs.

What's included, what's extra

Genuinely included, and worth crediting:

• •The medical visit is free. No consult fee, no intake deposit. Several providers on our board charge one.
• •Shipping is free, quoted at 5–7 business days.
• •On rapamycin, the required blood work is included with the prescription. That matters: a product whose safe use depends on monitoring, sold with the monitoring bundled, is the right structure.
• •No membership. Nothing recurring sits on top of the medication itself.

Extra, or conditional:

• •Testing beyond the rapamycin monitoring is a separate purchase ($75–$949 depending on the panel).
• •Rapamycin is unavailable in NJ, NY, RI and HI.
• •Refills are conditional on compliance: "You must adhere to the required lab schedule to receive refills," and failure to comply "may result in your prescription being suspended or canceled." That is a restriction, and it is the right kind.

Clinical oversight: who prescribes, and what they check

AgelessRx names its clinical leadership, which most of this category does not. The site lists a Medical Director (Dr. Jenell Decker, MD), an Assistant Medical Director (Dr. Mirna Jadan, MD), a telehealth physician (Dr. Aaron Stecker, DO), a Medical Advisor (Dr. Terry Grossman, MD), and a VP of Operations and Applied Science with a PhD (Dr. Stefanie Morgan). Naming your prescribers is a meaningful signal in a field full of anonymous "licensed providers."

Two caveats a careful reader should hold. First, the Medical Director's listed longevity credential is from the American Academy of Anti-Aging Medicine (A4M) — a professional body, not one of the 24 member boards of the American Board of Medical Specialties, which recognises no anti-aging or longevity specialty. That is not a knock on the physician; it is a fact about how thin formal credentialing is in this whole field, which we unpack in what is a longevity doctor. Second, fulfilment is described as "a partnering pharmacy" without naming a facility or stating a 503A/503B designation — so you cannot verify which compounder made your vial.

The oversight that impressed us most is behavioural rather than structural: rapamycin refills are gated on lab compliance. A provider willing to cut off a paying subscriber who skips bloodwork is a provider whose oversight is not decorative.

The evidence behind what it sells

AgelessRx sells a menu of drugs with, collectively, no completed human trial showing extended lifespan. That is not a criticism unique to AgelessRx — it is true of the entire category — but a review has to say it plainly rather than let the catalog imply otherwise.

Rapamycin. The most reproducible lifespan extender in mice: fed late in life to genetically heterogeneous mice, it extended median and maximal lifespan in a landmark study². In humans, the best evidence is AgelessRx's own PEARL trial — 48 weeks, decentralised, double-blinded, placebo-controlled, 5 mg or 10 mg weekly. It found that intermittent low-dose rapamycin was relatively safe, with adverse events similar across groups. It also missed its primary endpoint: visceral adiposity did not change. Some secondary signals appeared in subgroups — lean tissue mass and self-reported pain improved in women on 10 mg — and the authors themselves concluded that future work "will aim to more comprehensively establish efficacy"¹. That is a fair and unusually candid readout, and we walk through it in detail in what the PEARL trial actually showed and rapamycin for longevity: hype vs evidence.

Metformin. The human longevity case rests on a mechanistic argument³ and one widely-cited observational finding — diabetic patients on metformin monotherapy showing better adjusted survival than matched non-diabetic controls in a UK database analysis⁴ — a result the authors themselves framed as a question, and one that confounding by indication can generate without any drug effect. Against it sits a randomised trial in which metformin blunted the gains from 12 weeks of aerobic training in older adults: attenuated improvements in whole-body insulin sensitivity and VO₂ max, and abrogated the exercise-driven increase in skeletal-muscle mitochondrial respiration⁵. Since cardiorespiratory fitness is among the strongest survival predictors ever measured⁶, a longevity drug that dulls exercise adaptation deserves more caution than a $25/month price tag conveys. Full treatment in metformin for longevity and rapamycin and metformin: the evidence.

NAD+. Oral nicotinamide riboside reliably raises NAD+ in healthy middle-aged and older adults and is well tolerated — that much is established⁷. What it does to you is a much thinner story: the strongest human trial to date improved 6-minute walk distance by about 17.6 metres in people with peripheral artery disease, in 90 participants, with the authors calling for a larger trial to confirm it⁸. That is a disease endpoint in a sick population, not a healthspan outcome in a well one. AgelessRx's NAD+ page nonetheless leads with "89% saw results by 2nd check-in" — an unblinded, self-reported figure from its own customer base, which is the weakest evidence class there is — and states that "Maintaining healthy NAD+ levels may slow down the aging process." Our full read is in NAD+ for longevity and do NAD+ and peptides actually extend lifespan.

Low-dose naltrexone. The one item on the menu with a genuine, if narrow, randomised case — a meta-analysis of four RCTs in 222 fibromyalgia patients found a significant reduction in pain scores and higher pressure-pain threshold versus placebo, though the fibromyalgia impact questionnaire and pain catastrophizing scale did not differ⁹. That is modest evidence for a pain indication. It is not evidence for longevity, and nothing about LDN's mechanism makes it one.

Sermorelin. A growth-hormone secretagogue, and the weakest thing on the menu. A landmark systematic review of growth hormone in healthy older adults found small body-composition changes, no proven functional benefit, and significantly more adverse events¹⁰. The downstream target, IGF-1, has a U-shaped relationship with mortality in meta-analysis — both low and high values associate with higher death rates¹¹ — so "raise it to feel younger" is not a coherent goal. Detail in peptides for longevity.

Where it's weak

1. The price is a floor, not a price. Covered above, and it is the central finding of this review. Two of the three products we could verify terms on price their headline as a quarterly prepay; one of those is also introductory. The flagship publishes no terms at all.

2. Menu breadth is a conflict, not just a convenience. AgelessRx both recommends and dispenses roughly four dozen products, several of which (sermorelin, NAD+ in four formats, glutathione) have no meaningful human outcome data. A wide catalog run by the same entity that decides what you need is a structural incentive to find you something. That does not make the prescribing wrong — it means the burden of evidence honesty on the marketing copy is higher, not lower.

3. The research operation is a genuine asset and a genuine conflict. PEARL is AgelessRx-funded and AgelessRx-authored, testing a drug AgelessRx sells. The affiliations are disclosed on the paper, and the trial reported a null primary endpoint, which is about as strong a good-faith signal as an interested party can send. But a vendor's own trial on its own product is still a vendor's own trial, and the same site that publishes it also markets rapamycin as "the most promising longevity therapy today."

4. The pharmacy is unnamed. "Partnering pharmacies" tells you nothing you can verify.

5. No included human support. There is no bundled nurse or dietitian contact of the kind a support-included program provides — the offer is prescriber plus pharmacy plus shipping.

Who should skip it

• •Anyone who needs to know the annual cost before committing. If you cannot start without a firm number, you will have to complete an intake to get one — and on rapamycin, there is no way around that.
• •Anyone shopping on price alone. A rate that only holds if you prepay a quarter is not comparable to a genuine flat monthly rate, and the two should not be lined up in a spreadsheet as if they were.
• •Anyone who wants diagnostics first. AgelessRx sells tests but is not built around them. If your goal is a broad panel with a clinician reading it, a lab membership does that better and cheaper — see our best longevity blood test services roundup and the Function Health review.
• •Anyone buying sermorelin as an anti-aging intervention. The evidence does not support it, at any price.
• •Anyone hoping a prescription substitutes for the boring levers. Cardiorespiratory fitness⁶ and grip strength — which outpredicted blood pressure across 17 countries in the PURE study¹² — are not on any AgelessRx order form.

How it compares to the rest of our board

Against the lab-gated memberships, AgelessRx wins on structure and loses on clarity. Hone Health makes you buy a $65 biomarker test and then a $25 or $155 monthly membership before a prescription exists — but every drug on Hone's site is priced "From $X/mo + membership" with "No commitments. Cancel anytime" stated in plain language, so you can build the whole bill before you enter a card number. AgelessRx removes the membership and the lab gate entirely, then makes the bill unbuildable. Different failure modes; a buyer should pick which one they mind less.

Against Lifeforce — $349 starter plus $129/month for a narrow panel with a prescriber attached — AgelessRx is dramatically cheaper for someone who wants the prescription and not the quarterly retesting cadence, and dramatically thinner for someone who wants the monitoring.

Against the concierge tier, it is not a comparison: AgelessRx is a pharmacy with a prescriber, not a diagnostics program. The bands are mapped in concierge vs membership longevity.

Where it stands relative to every graded provider, including the ones we earn nothing from, is on our longevity provider rankings.

The grade, against our rubric

Five axes, weighted as our methodology publishes them:

• •Clinical oversight (25%) — strong. Named medical director and prescribers, free clinician visit, and refills genuinely gated on lab compliance. Docked for an unnamed compounding pharmacy and for a longevity credential (A4M) that no ABMS board recognises.
• •Evidence honesty (30%) — good, with a marketing gap. Funding and publishing a null-primary-endpoint RCT on your own flagship product is the strongest evidence-honesty signal in this category. The same site then sells sermorelin and runs an "89% saw results" self-report on NAD+, which pulls the axis back down.
• •Transparency (20%) — weak. The decisive failure. Headline prices are quarterly and, in at least one case, introductory rates; the flagship's month-to-month price is not published at all.
• •Price-to-value (15%) — strong. No membership, free consult, free shipping, rapamycin monitoring included. On a per-molecule basis this is among the better deals on the board — assuming the quoted rate is what you actually pay.
• •Conflicts of interest (10%) — mixed. Vertical dispensing across a four-dozen-item catalog, plus a self-funded trial on a self-sold drug. Disclosed, but real.

That combination lands a B+: a materially better structure than the membership programs it competes with, held back from the top band by a pricing presentation that a buyer cannot audit before handing over a medical history.

Bottom line

AgelessRx does two things almost nobody else in direct-to-consumer longevity does: it names its prescribers and it publishes trial results that did not go its way. It also removes the two costs that make this category expensive — the membership fee and the mandatory diagnostic onboarding — so a buyer who already knows which molecule they want can get a US-licensed prescriber and a pharmacy without paying a wrapper fee first.

What it will not do is tell you what things cost. "Starting at $65" for rapamycin is a floor with no terms attached; the two products where AgelessRx does explain the number reveal that the number is a quarterly prepay, and on NAD+ an introductory one at that. Buy here if you want the widest legitimate longevity menu with real prescriber oversight and no membership, and you accept that you will learn your real monthly bill inside the intake. Look elsewhere if a price you can verify before you start is part of what you are buying — and go in clear-eyed that rapamycin's best human trial, run by this company, missed its primary endpoint, and that metformin, NAD+ and sermorelin are being sold well ahead of their human evidence. Our full graded field, and what each provider actually charges, is at our longevity provider rankings.